Comparison of Tamoxifen and Toremifene as Adjuvant Treatment in Node-negative Postmenopausal Breast Cancer

ABSTRACT

PURPOSE: To evaluate the differences in therapeutic efficacy and toxicity profiles between adjuvant toremifene and tamoxifene in postmenopausal breast cancer patients. METHODS: Toremifene 40 mg (n=115) and tamoxifen 20 mg (n =116) were administered daily for more than 2 years after curative surgery for lymph node-negative breast cancer. Toxicity profiles were compared between the two groups and the patient survival rate was also analyzed. RESULTS: Sweating and hot flashes were the most common symptoms in the two groups (toremifene vs. tamoxifen= 47.8% vs. 49.1%). Increase of vaginal discharge (39.1% vs. 36.2%) and weight gain (21.7% vs. 24.1%) were the next following adverse effects. There was no significant difference in adverse effect between the two groups. During the median follow-up period of 25 months (range: 9~38 months), five (4.3%) and four (3.3%) patients treated by toremifene and tamoxifen, respectively, had recurrent disease. CONCLUSION: The clinical outcome and adverse effect profiles of toremifene were similar to those of tamoxifen. Toremifene at 40 mg/day seems to be as safe and effective as tamoxifen at 20 mg/day in the treatment of postmenopausal, node-negative, breast cancer. However, a longer follow-up study is needed to verify this.